These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15551162)

  • 1. EORTC-NCI-AACR--16th Symposium. Kinase inhibitors. 28 September-1 October 2004, Geneva, Switzerland.
    Lunec A
    IDrugs; 2004 Nov; 7(11):965-7. PubMed ID: 15551162
    [No Abstract]   [Full Text] [Related]  

  • 2. EORTC-NCI-AACR--16th Symposium. Molecular targets and cancer therapeutics. 28 September-1 October 2004, Geneva, Switzerland.
    Lunec A
    IDrugs; 2004 Nov; 7(11):961-4. PubMed ID: 15551161
    [No Abstract]   [Full Text] [Related]  

  • 3. EORTC-NCI-AACR--16th Symposium. Highlights. 28 September-1 October 2004, Geneva, Switzerland.
    Susman E
    IDrugs; 2004 Nov; 7(11):968-70. PubMed ID: 15551163
    [No Abstract]   [Full Text] [Related]  

  • 4. AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 1.
    Searle B
    IDrugs; 2007 Dec; 10(12):833-5. PubMed ID: 18041673
    [No Abstract]   [Full Text] [Related]  

  • 5. Medicinal Chemistry - XXth International Symposium. Lead finding strategies and kinase selectivity.
    Rotella DP
    IDrugs; 2008 Nov; 11(11):774-8. PubMed ID: 18988116
    [No Abstract]   [Full Text] [Related]  

  • 6. American association for cancer research--96th annual meeting. Kinases.
    Phillips T; Collins T; Davies J
    IDrugs; 2005 Jun; 8(6):458-60. PubMed ID: 15906186
    [No Abstract]   [Full Text] [Related]  

  • 7. AACR-NCI-EORTC-15th symposium molecular targets and cancer therapeutics: enzyme inhibitors and anti-angiogenics.
    Mayfield R
    IDrugs; 2004 Jan; 7(1):19-21. PubMed ID: 14968809
    [No Abstract]   [Full Text] [Related]  

  • 8. 14th EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics," November 19-22, 2002, Frankfurt, Germany.
    Evans AE
    Med Pediatr Oncol; 2003 Dec; 41(6):541-4. PubMed ID: 14595711
    [No Abstract]   [Full Text] [Related]  

  • 9. A new screening method for ATP-independent kinase inhibitors identifies repurposed anti-cancer drugs.
    Timaner M; Shaked Y
    EBioMedicine; 2018 Nov; 37():21-22. PubMed ID: 30509398
    [No Abstract]   [Full Text] [Related]  

  • 10. American Chemical Society--233rd National Meeting. Novel drugs for the treatment of cancer. 25-29 March 2007, Chicago, IL, USA.
    Turner B; Bright J
    IDrugs; 2007 May; 10(5):300-1. PubMed ID: 17487775
    [No Abstract]   [Full Text] [Related]  

  • 11. AACR-NCI-EORTC-15th symposium molecular targets and cancer therapeutics: emerging targets and pharmacodynamics.
    Mayfield R
    IDrugs; 2004 Jan; 7(1):22-5. PubMed ID: 14968810
    [No Abstract]   [Full Text] [Related]  

  • 12. Deal watch: Bristol-Myers Squibb and Exelixis collaborate on kinase inhibitors.
    Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180098
    [No Abstract]   [Full Text] [Related]  

  • 13. AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 3.
    Collins T
    IDrugs; 2007 Dec; 10(12):840-3. PubMed ID: 18041675
    [No Abstract]   [Full Text] [Related]  

  • 14. Advancing the kinase field: new targets and second generation inhibitors.
    Laufer S; Bajorath J
    J Med Chem; 2015 Jan; 58(1):1. PubMed ID: 25490234
    [No Abstract]   [Full Text] [Related]  

  • 15. Approval heralds new generation of kinase inhibitors?
    Fletcher L
    Nat Biotechnol; 2001 Jul; 19(7):599-600. PubMed ID: 11433254
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA-approved small-molecule kinase inhibitors.
    Wu P; Nielsen TE; Clausen MH
    Trends Pharmacol Sci; 2015 Jul; 36(7):422-39. PubMed ID: 25975227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted agents for advanced thyroid cancer: "knowledge is power" - the role of multikinase inhibitors.
    Mangano A; Kim HY; Lianos GD; Roukos DH; Dionigi G
    Future Oncol; 2014 Nov; 10(14):2099-102. PubMed ID: 25471022
    [No Abstract]   [Full Text] [Related]  

  • 18. AACR-NCI-EORTC--21st International Symposium. Molecular targets and cancer therapeutics--Part 2.
    Walker K; Padhiar M
    IDrugs; 2010 Jan; 13(1):10-2. PubMed ID: 20024839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AACR-NCI-EORTC International Conference 2009.
    Awada A; Lacombe D
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):319-20. PubMed ID: 20214512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.
    Garlich JR; De P; Dey N; Su JD; Peng X; Miller A; Murali R; Lu Y; Mills GB; Kundra V; Shu HK; Peng Q; Durden DL
    Cancer Res; 2008 Jan; 68(1):206-15. PubMed ID: 18172313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.